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Abstract – Since the entrance of Tunisia to the World Trade Organisation (WTO) in 1995, the 
Tunisian pharmaceutical industry has recorded considerable changes. Notably, with the extension 
of  patentability  to  pharmaceuticals,  the  sector  is  now  at  a  dynamic  stage  of  transformation, 
translated by a notable development of the industry of generics. The purpose of this paper is to 
analyze the mutations that have marked the Tunisian pharmaceutical industry over the last decade 
and study its potential of developing future innovation. In this purpose, the paper is divided into 
two main parts. In the first one, we are going to present the legal and economic changes in the 
Tunisian pharmaceutical sector and highlight the emphasis of the government on the production 
of generics. In the second part, the paper aims at studying the perspectives for innovation in 
Tunisia through the study of the innovation capabilities in the Tunisian pharmaceutical sector. 
The results show that in spite of some strengths of the Tunisian economy, the perspectives for 
pharmaceutical innovation remain handicapped by several financial and structural deficiencies of 
the national and pharmaceutical innovation systems. 
Key Words: Generics; Innovation; Innovation System; Patents; Pharmaceuticals; Tunisia. 
 
Résumé – Depuis l’adhésion de la Tunisie à l’Organisation Mondiale du Commerce (OMC) en 
1995, le secteur pharmaceutique tunisien enregistre des changements considérables. Il se situe 
aujourd’hui  à  un  stade  dynamique  de  transformations,  traduites  particulièrement  par  le 
développement notable de l’industrie des génériques. L’objectif de cet article consiste donc à 
analyser  les  mutations  ayant  marqué  le  secteur  pharmaceutique  tunisien  durant  la  dernière 
décennie et d’étudier son potentiel d’innovation. Dans cette perspective, l’article s’articule autour 
de deux grandes parties. Dans la première, nous allons exposer les changements réglementaires et 
économiques du secteur pharmaceutique tunisien et mettre l’accent surtout sur l’incitation du 
gouvernement pour la production des génériques. Dans la seconde partie, nous nous proposons 
d’étudier les perspectives d’innovation en Tunisie à travers l’étude des capacités d’innovation 
locales dans le secteur pharmaceutique. Les résultats montrent qu’en dépit de certaines forces qui 
caractérisent l’économie tunisienne par comparaison à d’autres Pays En Développement (PED) 
similaires, les perspectives d’innovation pharmaceutique demeurent handicapées par nombreuses 
défaillances  financières  et  structurelles  liées  aux  systèmes  national  et  pharmaceutique 
d’innovation. 
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INTRODUCTION 
 
The last century has shown a considerable spread of patent rights among developing countries. This 
movement has been led, in a large part, by pressures exercised especially by the United-States. It is in 
this same vein that, in 1995, Tunisia took the engagement to establish and strengthen its patent system 
conformingly to the TRIPs
1 agreement. However, this engagement lifts up several conflicts about the 
mitigated impacts that are expected from patent enforcement on the Tunisian economy. This debate 
has  become  even  more  stretched  with  the  extension  of  patent  protection  to  the  pharmaceutical 
industry, since, in addition to its economic dimension, the question has worn henceforth a social 
dimension dealing with public health. In fact, December 2004 represented the end of the transitory 
period granted to Tunisia (among other developing countries) to recognize pharmaceutical patents; an 
event that is expected to generate a major bend in the Tunisian pharmaceutical industry. Although 
pharmaceutical patents are relatively a recent issue in Tunisia, their short-term impacts have already 
started showing up on the Tunisian market, translated by a pharmaceutical policy more centered on 
the  industry  of  generics.  On  the  other  hand,  according  to  developed  countries,  the  aim  from 
establishing  patent  systems  is  at  first  enhancing  the  activity  of  innovation,  which  is  a  long-term 
impact.  In  this  context,  the  questions  that  come  into  mind  at  this  stage  are:  To  what  extent  is 
improving the production of generics beneficial for the Tunisian pharmaceutical industry? And are the 
innovation  capabilities  in  Tunisia  promising  for  potential  pharmaceutical  innovation?  In  order  to 
answer these questions, our paper will be divided into two main sections. In the first one, we are going 
to present the legal and economic changes in the Tunisian pharmaceutical sector and highlight the 
emphasis of the government on the production of generics. In the second section, we will focus on 
studying the innovation capabilities in the Tunisian pharmaceutical sector, extract its strengths and 
weaknesses and propose some corrective measures. 
 
 
1. TRANSFORMATIONS OF THE TUNISIAN PHARMACEUTICAL SECTOR 
 
The  patentability  of  pharmaceuticals,  expected  since  1995  and  put  into  practice  since  2005,  has 
generated several changes in the Tunisian pharmaceutical sector over the last decade. These changes 
have  considerably  marked  the  legal  framework  towards  more  improved  patent  rights  and  a 
pharmaceutical policy more centred on the industry of generics (1.1). In this same vein, the adjustment 
of  the  legal  framework  has  in  its  turn  generated  economic  transformations  of  the  Tunisian 
pharmaceutical  sector,  especially  in  terms  of  the  market  structure,  the  distribution  network 
organization and the notable increase of the local production, especially of generics (1.2). This last 
effect  lifts  up  wonderings  about  how  beneficial  could  this  public  policy  be  for  the  Tunisian 
pharmaceutical industry and more globally for the whole economy (1.3). 
 
1.1. Pharmaceutical Patents in Tunisia: Evolution of the Legal Framework  
 
Pharmaceutical patent rights in Tunisia seem to have roots far back in history. However, they have 
drawn attention only recently because of the considerable changes they have recorded since the mid-
1990s. In fact, the changes in the legal framework have been translated not only by the patent law 
reform  (1.1.1),  but  also  by  a  pharmaceutical  policy  basically  centred  on  the  industry  of  generics 
(1.1.2). 
 
1.1.1. The Patent Law Reform in Tunisia 
 
According to the TRIPs agreement, a patent is defined as a strongly exclusive industrial property right 
which  grants  to  its  holder  a  temporary  “monopoly”  power  over  20  years  on  his  innovation.  This 
monopoly  power  allows  the  patent  holder  to  prevent  third  parties  from  exploiting  the  patented 
                                                 
1 “TRIPs” is the abbreviation of Trade Related Intellectual Property Rights.   5
invention without his agreement  (WTO, 1994,  TRIPs). Patent protection in Tunisia is recognized 
since 1888. In fact, the decree of the 26
th of December 1888 stipulates patent protection for inventions 
in all the industries. In this context, the decree defines a patentable invention as “the invention of new 
industrial products, the invention of new means or the new application of already existent means in a 
way to generate a new or an improved industrial product” (WIPO, 2000, Decree of December 26
th, 
1888,  Article  1
2).  However,  concerning  the  pharmaceutical  sector,  the  decree  does  not  recognize 
product patents: “for inventions related to food or to pharmaceuticals, exclusively process patents can 
be granted but not product patents” (WIPO, 2000, Decree of December 26
th, 1888, Article 2). The 
main objective of the government was the protection of public health and, subsequently, guaranteeing 
the accessibility of the population to essential drugs. In fact, pharmaceutical patents are supposed to 
increase drugs prices and thus to make them less accessible to lower-income people; this explains the 
exclusion of pharmaceutical products from patentability. 
 
Patent rights remain responsible for the increase of drugs’ prices. At the same time, the main objective 
of  the  Tunisian  government  remains  preserving  public  health.  However,  the  laws  have  changed 
allowing patentability of pharmaceuticals in Tunisia since the ratification of TRIPs agreements in 
1995. This change is rather an obligation for developing countries members of the WTO. In fact, the 
entry to the WTO means automatically the acceptation of all its agreements, including the TRIPs, 
conformingly to the principle of “all or nothing”. Subsequently, all the member countries of the WTO 
have  to  adjust  their  intellectual  property  legislation  conformingly  to  the  TRIPs  measures  with  a 
prerogative  of  a  5  years  transitory  period  for  developing  countries  to  revise,  progressively,  their 
legislations  and  5  additional  years  to  recognize  patents  in  some  specific  sectors,  such  as 
pharmaceuticals
3. It is in this same vein that Tunisia reformed its patent system and started granting 
pharmaceutical patents since 2005. We mention here that the “National Institute of Standardization 
and  Industrial  Property”  (INNORPI)
4  in  Tunisia  was  assumed  to  accept  pharmaceutical  patent 
applications since 1995 and put them into a “mailbox”. In other words, from 1995 to December 2004, 
pharmaceutical  patent  applications  were  examined  and  those  of  them  accepted  were  put  into  the 
mailbox but not granted until January 2005, when the institute started granting them conformingly to 
the TRIPS measures (in terms of the conditions of patentability, the minimal protection period of 20 
years, the exceptions for patentability … etc) (El Kateb, 2005; Musungu & Oh, 2006).  
 
In these conditions, since 2005, any patented drug copied and produced in Tunisia is considered as an 
infringement to the patent and brings about problems to the producer, in this case considered as an 
imitator. However, local firms can contract licences or produce copies of the brand name drug once 
the patent expires; these copies are called “generics”. In other words, a generic drug is a drug whose 
patent expired after a protection period of 20 years. The production of generics submits to a tight 
control  by  the  World  Health  Organization  (WHO)  through  the  intermediation  of  local  medical 
institutions
5 in order to guarantee the same high quality as the brand name drug (Coriat & Orsi, 2003). 
This  explains  that  the  patented  drug  and  the  generic  one  are  medically  equivalent  therapeutics. 
However, generics remain much less expensive than the original version of the drug since they are 
freed from expenditures in R&D. In this context, pharmaceutical patent improvement in developing 
countries is meant to transform the status of drugs imitation from an illegal (counterfeiting) into a 
legal phenomenon. Generics can, in fact, be perceived as a kind of a “legal imitation” since they are 
approved by laws. At the same time, according to the definition of Schumpeter (1934), generics are 
considered as an innovation, since they are existent products newly brought to the local market, which 
is the case of Tunisia. In addition to generics, the patent law in Tunisia expects a certain number of 
                                                 
2 The decree of December, 26
th, 1888 was revised in 2000, generating the Law No. 2000-84 of August 24
th, 2000, on 
Patents in Tunisia. 
3 The transitory period of establishing patent systems in the Least Developed Countries (LDC) is extended to 2016. 
4 Institut National de la Normalisation et de la propriété Industrielle (INNORPI). 
5 For example: The Central Pharmacy of Tunisia and the Pasteur Institute are supposed to control the production of 
generics in Tunisia.   6
exceptions  in  order  to  conciliate  between  protecting  laboratories’  interests  and  guaranteeing  the 
accessibility of lower-income people to essential drugs.  
i- The obligatory licences: according to the article 69 of the patent law N°2000-84 of the 24
th of 
August, 2000, the Tunisian government authorises the grant of obligatory licences in 4 years counted 
from the date of patent application or in 3 years counted from the date of grant
6 and this in three cases 
(WIPO, 2000):  
-  1
st case: hen the patented invention was not industrially used within 4 years counted from the date 
of  application  or  3  years  counted  from  the  date  of  grant  (the  longest  period  is  considered). 
Nevertheless,  if  the  patented  invention  benefits  from  a  preliminary  market  authorization,  the 
obligatory licence could be granted after 6 years counted from the date of application or 3 years 
counted from the date of grant, on the basis of the longest period; 
-  2
nd case: if the quantities of the brand-name drug supplied by the patent holder do not cover the 
Tunisian market needs; 
-  3
rd case: when the patented drug has not been industrially or commercially used in Tunisia anymore 
for more than 3 years.  
ii- The automatic licences: they  represent another mechanism that restrains pharmaceutical patent 
protection. In fact, the article N°79 of the law N°2000-84 on patents allows the grant of an automatic 
licence of a patented drug that is not or insufficiently commercialized or sold at abnormally high 
prices on the Tunisian market. These licences aim at prevailing public health considerations above 
patent holders’ interests. 
iii- Exclusion from patentability: in order to facilitate the access to drugs, the article N°47 of the 
patent law in Tunisia stipulates that patentability can not be extended to pharmaceutical solutions 
prepared in pharmacies on the basis of a medical prescription and to necessary acts for the production 
of generics. 
 
Hence,  we  notice  that  these  exceptions  are  considerably  inspired  from  the  TRIPs  agreement  and 
especially from the measures inherent to the Doha declaration. In fact, the declaration adopted in 
Doha on the 14
th of November 2001, is expected to conciliate between the interests of both developing 
countries and patent holders. However, some of the measures inherent to this declaration seem to be 
contradictory: on the one hand, in its 6
th paragraph, the Doha declaration allows obligatory licences 
and  calls  for  a  measure  that  could  enable  using  them  in  developing  countries  where  production 
capabilities are insufficient. On the other hand, obligatory licences are allowed only for a certain 
number of diseases presented in a list published and revised yearly by the WTO. In fact, developing 
countries  and  non  governmental  organizations  -such  as  Doctors  Without  Borders-  estimate  that 
obligatory  licences  are  not  very  efficient  since  they  are  allowed  only  for:  (i)  diseases  of  which 
therapies exist but their patents have already expired; (ii) diseases for which there are no therapies yet 
and  (iii)  diseases  for  which  R&D  efforts  are  insufficient,  in  the  sense  that  the  probability  of 
developing cures for these diseases is very small at least in the near future (DWB
7, 2003). Although 
the aim from the Doha declaration is to facilitate accessibility of lower-income countries to essential 
drugs, its measures, especially the exclusion of the most important patents from obligatory licences, 
show  that  this  declaration  benefits  to  pharmaceutical  laboratories  on  the  expense  of  developing 
countries. In this context, Tunisian pharmaceutical firms for example could not apply for an obligatory 
licence for cancer or AIDS treatments even in the presence of one or more of the three previously 
mentioned conditions that are required for granting obligatory licences. At this stage, the conclusion 
that  comes  into  mind  is  that  pharmaceutical  patents  do  not  have  positive  effects  on  developing 
countries.  At  the  same  time,  it  is  obvious  that  in  the  absence  of  patent  protection  private 
pharmaceutical  enterprises  would  not  be  incited  to  innovate  and  diffuse  their  innovations  in  the 
developing as well as in developed the countries. In this sense, the establishment of pharmaceutical 
patents in Tunisia would not only be the result of its entry to the WTO but also it would stem from a 
policy  that  aims  at  providing  the  appropriate  legal  infrastructure  to  improve  the  country’s 
                                                 
6  The  shortest  period  is  taken  into  consideration.  If  the  patented  drug  benefits  already  from  a  preliminary  market 
authorization, this period is of 6 years counted from the date of application or of 5 years counted from the date of grant. 
7 Doctors Without Borders.   7
attractiveness to pharmaceutical multinational firms as well as to enhance the motivation for the local 
firms to innovate. 
 
1.1.2. The Emphasis on the Production of Generics in Tunisia 
 
Among  the  objectives  stated  in  the  8
th  development  plan  (1992-1996),  the  government  aims  at 
achieving a level of 60% of pharmaceutical local production by the end of 1996. Nevertheless, we 
notice that this goal was not achieved even 11 years later, since until 2007, the local production 
represents only 50%. It is in this context that Tunisia stresses currently much on enhancing the local 
production.  In this purpose, the  government expects several advantages which  are specific to the 
pharmaceutical industry (WHO, 2003): 
i-  Fiscal advantages: pharmaceutical firms benefit of: exoneration from duties on the raw materials 
and the packaging items; reduction of the duties on imported equipments and an encouraging VAT
8 
rate; 
ii- In  a  commercial  framework:  the  local  pharmaceutical  firms  have  the  prerogative  to  ask  the 
government for a suspension of imports of similar products, provided that the pharmaceuticals stock 
hold by the local producer satisfy the market demand in the lack of imports; 
iii-  The  legal  measures:  by  the  law  promulgated  on  of  September  the  10
th,  1996,  the  cooperation 
between pharmaceutical laboratories and the optimisation of production capabilities have been made 
possible since the authorization to subcontracting between laboratories. 
 
However, the most important measure remains the last reform of the social security system in July 
2007 and according to which the National Fund of Health Insurance (CNAM) reimburses patients on 
the basis of the least expensive therapeutic equivalent on the market (MPH, 2008). Since generics are 
less expensive than the brand name and the licensed drugs, this reform aims at improving the market 
demand  for  generics  and  subsequently  at  enhancing  their  production.  This  reform  is  supposed  to 
reduce  health  expenditures.  In  this  context,  a  similar  reform  has  been  put  into  place  in  France. 
According to a survey led by the French National Fund of Health Insurance, this reform is expected to 
contribute at saving between 12 and 17 million Euros yearly in health expenditures in France (Icart, 
2008).  Since  the  health  insurance  reform  in  Tunisia  is  still  new,  its  long-term  impacts  are  not 
perceived yet. However, in the short-term we notice already important changes in the pharmaceutical 
market structure, particularly characterised by a greater potential of production especially in generics. 
 
1.2. Main Characteristics and Evolution of the Tunisian Pharmaceutical Sector 
 
The pharmaceutical industry in Tunisia is led by a strong public sector developed by the government 
since the early 1960s. In fact, until the mid-1980s there were only three pharmaceutical enterprises in 
Tunisia, all of them public. However, it is in the framework of the privatisation movement put into 
place since 1987 that the government started encouraging the development of the private investment 
in all the sectors including the pharmaceutical sector. Currently, the Tunisian pharmaceutical industry 
is represented by 30 firms: two public (the SIPHAT
9 and “Pasteur” Institute), 23 private and five 
subsidiaries of multinational firms (Pfizer, Baxter and BMS-UPSA from the USA and Pierre-Fabre 
and Sanofi-Aventis from France). 
                                                 
8 Value Added Tax. 
9 La Société des Industries Pharmaceutiques de Tunisie: The Tunisian Pharmaceutical Industries Company   8
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In fact, the privatisation movement has contributed at “freshening up” the Tunisian pharmaceutical 
industry which recorded an annual average growth rate of 13% over the last ten years against a world 
rate of 7% (MPH, 2008).  
Graph -2- Pharmaceutical Investment in Tunisia (1989-2005) 
Ministry of Public Health, 2008 
 
The  foreign  direct  investments  (FDI)  led  by  multinational  firms  encouraged  by  the  privatisation 
movement in Tunisia, have notably revivified the Tunisian pharmaceutical industry. The graph above 
describes the growth trends of the total investment in the pharmaceutical industry in Tunisia which 
has considerably grown up over the last twenty years by an approximate multiplication by 43: from 
9,28 million TND in 1989 up to 400 million TND in 2005, of which the share of foreign subsidiaries 
represents  an  average  value  of  40%.  In  this  same  vein,  the  increase  in  the  number  of  private 
pharmaceutical firms in Tunisia has generated a considerable augmentation of the local production; 
grown up from only 8% in 1987 to 44% in 1999 to achieve 50% in 2007 (WHO, 2003; MPH, 2008). 
The local production is constituted by generics as well as by licensed products. Lately, we notice a 
notable decrease in the share of licensed drugs for the profit of generics, which represent more than 
half of the local production. In fact, the share of generics increased from 21% in 1999 to 40% in 2005 
to stand at 51% in 2007. Nevertheless, we notice a slight slow down in the growth rhythm of generics 
translated by an annual average growth rate of 13% over the period 1999-2005 and of 11,2% over the 
period 2005-2007. This slow down is explained by the increase of the market needs in treatments 
whose patents have not expired yet such as certain versions of anticancer medicines (MPH, 2008). 
Graph -3- Composition of the Local Pharmaceutical Production in Tunisia (1999-2007) 
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Furthermore, in spite of the improvement of the share of generics, exports remain at a low level, 
representing only 5 to 7% of the total production (the equivalent of 12 to 15 million Euros). Exports 
are intended for more than 23 foreign markets, some of them for political considerations (notably 
Iraq),  some  other  for  geographic  factors  (such  as  Morocco,  Algeria,  and  Libya)  and  others  for 
economic factors (such  as France  and Switzerland). Among these 23 countries, only  six of them 
absorb 86,7% of these exports: Libya (40,5%), France (15,8%), Switzerland (9,8%), Morocco (8,7%), 
Algeria ((7,8%) and Iraq (4,1%). The other share of exports (13,3%) is basically in destination of 
some sub-Saharan African and Middle-eastern countries (MPH, 2008). 
 
As for the other 50% of the market needs, they are covered by imports which are assured exclusively 
by the Central Pharmacy of Tunisia (CPT). In addition, the Pasteur Institute has the monopole of 
importing vaccines, serums and allergens
10. These two institutions head the distribution network of the 
Tunisian  pharmaceutical  market.  They  have  the  exclusive  right  to  import  pharmaceuticals  and 
distribute them to hospitals, wholesalers and some other public medical organisms such as social 
security institutions. 












Source: The author on the basis of the Ministry of the Public Health’s Data (2008). 
 
Monopolizing pharmaceutical imports inside the public sector stems from a national policy that aims 
at a tighter control of imported products. This measure has become more judicious after the discovery 
of the virus of hepatitis C in a stock of blood imported from France (WHO, 2003). In this context, the 
privatisation  of  the  pharmaceutical  industry  remains  at  the  national  level.  In  fact,  lately  the 
government  allows  the  wholesalers  to  supply  directly  pharmacies  with  locally  produced 
pharmaceuticals (licensed products and generics), without necessarily getting through the CPT while 
all imports remain assured by the public sector. We notice that the share of generics in the public 
distribution network (45%) is larger than in the private network (10%).  
 
In  response,  the  Tunisian  government  stresses  more  and  more  on  improving  the  production  of 
generics. This decision stems from a policy that aims basically -among other objectives- at countering 
the increase of drugs prices due to pharmaceutical patents on the one hand and to the evolution of 
exchange rates on the other hand. However, the industry of generics seems to be a double-edged 
sword, generating as much negative as positive effects. 
 
1.3. Evaluation of the Tunisian Pharmaceutical Policy: Advantages and Limits of Generics  
 
In terms of value, health expenditures have significantly grown up in Tunisia; according to the WTO 
report, we recorded a multiplication by 2,3 over the last decade (MPH, 2008). At the same time, due 
to  the  increase  of  imported  and  licensed  brand-name  drugs  prices  on  the  one  hand,  and  to  the 
continuous increase of carburant prices and the depreciation of the Tunisian currency on the other 
hand, Tunisia, as a country with limited financial resources, is in front of big challenges about how to 
                                                 
10 An allergen is a non-parasitic antigen capable of stimulating a hypersensitivity reaction in atopic individuals. 
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assure the access to essential treatments. It is in this purpose that the government put into place a 
certain  number  of  measures  that  are  supposed  to  augment  the  share  of  local  production  and  this 
through  promoting  the  industry  of  generics.  Nevertheless,  too  much  emphasis  on  the  industry  of 
generics could be a double-edged sword for the Tunisian economy, presenting several limits (1.3.2) in 
addition to its numerous advantages (1.3.1). 
 
1.3.1- Generics Production and the Development of the Tunisian Pharmaceutical Industry 
 
As mentioned above, in terms of costs, it is obvious that generics are less expensive than the brand-
name drugs.  
Table -1- Comparison between three Brand-name Drugs and Generics’ Prices in Tunisia (in 
TND) 
  Amoxicilline 500 mg  Diclofénac 25 mg  Glibenclamide 25 
mg 
Brand-name drug  7,5  24,5  28,2 
Equivalent generic  4,6  12,6  7,0 
Source: WHO (2007) 
 
As shown in the table above, we notice that brand-name drugs are much more expensive than the 
equivalent  generics.  For  example,  for  the  case  of  Glibenclamide,  which  is  a  treatment  for  some 
diabetes, the price of the brand-name drug (28,7 TND) is four times more expensive than the generics 
version (7,0 TND). This difference influences considerably the accessibility of lower-income people 
to  drugs  especially  for  chronic  diseases  such  as  diabetic.  Subsequently,  substituting  generics  to 
imports  allows  the  government  to  control  and  reduce  health  expenditures  in  Tunisia  which  have 
grown up in terms of value but are maintained almost stable in percentage of GDP, as shown in the 
graph below. 
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Source: WHO (2007) 
 
Furthermore, the increase of the production of generics will reduce the imports of pharmaceuticals and 
subsequently contributes at saving currencies. Particularly, saving currencies represents a major goal 
for Tunisia, especially with the continuous depreciation of the Tunisian Dinar against the Euro (we 
restate here that more that 80% of imports are from the European Union and are thus made out in 
Euro). To remedy to this problem, the government stresses much on promoting exports in all the 
fields. Nevertheless, as we previously mentioned, pharmaceutical exports in Tunisia remain under the 
estimated level representing only 5 to 7% of the total production. However, in terms of value, exports 
of generics have considerably progressed over the last four years growing up from 10,1 million Dinars 
in 2004 to 19,4 million Dinars in 2007, which makes a growth rate of 92%. This confirms that also the 
production of generics is more targeted to the local market.  
 
Globally,  the  development  of  the  industry  of  generics  consolidates  the  local  industrial  tissue  by 
promoting investment and consequently increasing the employment rate. It is noticed here that the   11
pharmaceutical  firms  employ  3700  persons  of  32719  people  employed  by  the  chemical  sector  in 
Tunisia, which makes a share of only 11,3%. The pharmaceutical sector employs highly qualified 
workforce, especially pharmacists and engineers.  
 
More globally, all the benefits inherent to generics and presented above are themselves a vector that 
generates a more important benefit to the Tunisian economy; that is the attraction of pharmaceutical 
multinational firms. In fact, the generics-based policy has drawn the attention of foreign investors to 
the high potential of production of the Tunisian pharmaceutical industry. Therefore, several foreign 
laboratories, which are world experts in generics production, are becoming more and more interested 
in investing in Tunisia. The most revealing example is that three of the most important Indian firms -
Rambaxy, Cipla and Hetero Drugs- have signed joint-venture contracts with Tunisian pharmaceutical 
enterprises  in  order  to  produce  anti-infectious,  anti-cancer  and  anti-inflammatory  generics  (DEC, 
2007).  
 
In addition, the Tunisian economic policy encourages the production of generics as an alternative to 
avoid or at least to minimize the dependency of local licensees towards foreign firms. In fact, in 
opposition to generics, local firms have to negotiate with brand-name laboratories for licences. It is 
noticed here that in this kind of negotiations, local firms are the passive partner and consequently they 
have to accept the contract that serves most the interests of the foreign laboratory. This could have 
negative  effects to the licensee especially in terms of drugs prices. At  the same time, even after 
obtaining the contract, the industry of licensed pharmaceuticals submits to several conditions: 
i-  The licensee has to import raw materials exclusively from the owner of the brand name product at 
fixed prices, independently from the evolution of exchange rates. In case of depreciation of the Dinar, 
this negatively affects as much local consumers (due to the increase of prices) as the Balance of 
Payments (due to a bigger loss of currencies); 
ii- The licensee can not export, even partially, his production; 
iii-  The owner of the brand name product has the exclusive right to retrieve the license at anytime, on 
the basis of a simple notification few months before. Therefore, the local production depends always 
on the owner’s strategy and remains thus insecure for the licensee.  
Similarly to any other phenomenon, in spite of its many advantages for Tunisia, generics production 
presents many limits. 
 
1.3.2. Generics: A Short Term Strategy 
 
The most important limit is that generics producers remain dependent on the original drug owner, 
since they sell only copies of the brand name drug and thus they have to wait until the patent expires 
so that they could produce a copy from the patented drug. In this sense, the local firms submit to a 
kind of a phase of “inertia” which is equal to the patent life of the brand name drug. This phase could 
have serious negative impacts, especially when dealing with diseases that need an urgent intervention, 
especially  cancer.  In  fact,  cancer  deaths  are  more  and  more  increasing  in  Tunisia.  Despite  the 
reimbursement by the social security, cancer cures remain very expensive and inaccessible for the 
lower-income class in Tunisia especially they are long duration treatments. 
 
In addition, much emphasis on the production of generics in Tunisia could have the side effect of 
spreading a sort of passiveness towards innovating within local pharmaceutical firms. In other words, 
local  pharmaceutical  firms  would  be  more  willing  to  behave  as  innovation  takers  rather  than  as 
innovation makers, since the encouragement is put much more on the production of generics than on 
producing new products or ameliorating existing (Yacoub, 2008a). This consolidates the thesis that a 
generics-based pharmaceutical policy remains a short-term solution. In fact, this policy allows the 
country to counter many problems as mentioned previously but, all alone, it is inadequate to achieve 
the goal of establishing a solid pharmaceutical industry, which constitutes a long-term objective. In 
this perspective, the government should mobilize more efforts in order to kick-start the pharmaceutical 
industry.  Theoretically,  the  establishment  of  pharmaceutical  patents  constitutes  a  determinant  of   12
innovation in pharmaceuticals. However, the question here is whether they are sufficient to generate 
pharmaceutical innovation in Tunisia. A priori, it is obvious that pharmaceutical innovation requires 
more “ingredients” in addition to a strong patent system.  In this perspective, the next section of this 
paper aims at studying the innovation capabilities in the Tunisian pharmaceutical sector. 
 
 
2. PERSPECTIVES FOR PHARMACEUTICAL INNOVATION IN TUNISIA  
 
Due to the disparate character of innovation, it is imperative to begin first by defining this concept and 
highlight its different types, in order to better understand its relationship with patents. According to 
Schumpeter (1934), innovation is defined as a new combination of the resources of production. More 
precisely, he enumerates five forms of innovation: producing new products, introducing new methods 
of production, opening up new outlets, using new inputs and realizing a new organization of the 
production. In these conditions, producing already existing generics by local producers represents an 
innovation for Tunisia, since these products are new for the Tunisian pharmaceutical market. Also, 
improving existing drugs by Tunisian pharmaceutical firms is considered as an innovation. Globally, 
the category of innovation depends much on the local production and innovation potential. It is in this 
purpose that we will study the input (2.1), throughput (2.2) and output (2.3) innovation indicators in 
the Tunisian pharmaceutical sector. This study allows us to expose the strengths and weaknesses of 
the Tunisian innovation capabilities and thus to suggest some corrective measures (2.4). 
 
2.1. The Inputs of Pharmaceutical Innovation in Tunisia 
 
To  measure  the  inputs  of  innovation  in  the  Tunisian  pharmaceutical  sector,  we  will  take  into 
consideration  the  main  key  indicators  such  as  R&D  expenditures  (in  %  of  GDP),  tertiary  school 
enrollment, and infrastructure equipments (transport, telecommunications …). 
 
2.1.1. The Key Input of Innovation: Human Resources  
 
The development of the activity of innovation could not take place in the absence of qualified human 
resources.  Education  is  considered,  according  to  Lucas  (1988),  as  the  main  factor  of  knowledge 
acquisition and accumulation. Aware of the importance of human resources as an input of innovation, 
the  department  of  scientific  research  and  technology  of  the  MHESRT
11  organizes,  since  2003,  a 
cooperation  program  between  the  local  and  the  Tunisian  immigrant  researchers.  This  cooperation 
amounts  to  the  organization  of  projects  commonly  developed  by  the  local  and  the  immigrant 
researchers which projects are financed by the MHESRT. In the framework of this program, Tunisian 
universities  welcome  yearly  researchers  for  a  period  going  from  one  to  six  months,  in  order  to 
improve  researches  in  prior  and  strategic  fields  such  as  technologies  of  information  and 
communication, biotechnologies, agriculture, energy, environment, health, human and social sciences 
and engineering sciences (MHESRT, 2006a). To highlight the education level in Tunisia, we mention 
that in 2005, the tertiary school enrollment stands at 29%, which is relatively satisfactory, especially 
comparing with some other countries with similar economic indicators, such as Algeria (15%) and 
Morocco (12,2%). 
 
In the purpose of better surround the local pharmaceutical innovation capabilities it is interesting to 
study the characteristics of pharmacy education. In Tunisia there is only one faculty of pharmacy. 
Since its establishment in 1975, the number of students has more than doubled (a multiplication by 
2,4)  between  1987  and  2007:  from  595  students  to  1436  (Table  2).  However,  we  notice  a  light 
decrease in the number of pharmacy students over the three years from 2002 to 2004. This decrease 
could be explained by the increase of the unemployment rate in pharmacy. In fact, the number of 
                                                 
11 Ministry of Higher Education and Scientific Research of Tunisia.   13
pharmacy  graduate  students  on  the  waiting  list
12  is  continuously  increasing  due  to  the  market 
saturation in pharmacies (MPH, 2008). 
Table - 2 -Pharmacy students in Tunisia – Total Number (1976-2007) 
Scholar 
Year  1987/88  92/93  97/98  99/00  00/01  01/02  02/03  03/04  04/05  05/06  06/07 
Students  595  693  852  1144  1220  1281  1280  1270  1364  1399  1436 
Ministry of Higher Education, Scientific Research and Technology (MHESRT), Tunisia, 2008 
 
The  pharmacy  faculty  of  Monastir  has  a  good  reputation  in  terms  of  pharmaceutical  formation 
comparing with other pharmacy faculties in the Arab Maghreb Union
13 and the Middle East (MPH, 
2008). This is proved by the important number of foreign students which has risen up to achieve 35 in 
1997 and 1998 and 40 students in 2002. The graph 4 shows the decrease of the number of foreign 
pharmacy students, in terms of percentage of the total students’ number. In fact, the part of foreign 
pharmacy students has also decreased over the last five years. This decline could be explained either 
by a decrease in the number of foreign students, or an increase in the number of Tunisian students, or 
by both a decrease in the number of foreign students and an increase in the number of Tunisian 
students.  Actually,  we  notice  the  both  effects  i.e.  an  important  increase  (of  61%)  of  Tunisian 
pharmacy students between 2003 and 2007, and a decrease (of 35%) in the number of foreign students 
over the same period.  
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Since the establishment of the faculty of pharmacy, the number of Tunisian pharmacists is constantly 
increasing (from 1726 in 1990 to 2500 in 2001, reaching a number of 3497 in 2006) (MPH, 2008). In 
1998, 56% of pharmacists work for the private sector (they have founded their own pharmacies). The 
other  44%  are  distributed  between  hospitals,  public  and  private  biology  centers,  teaching, 
administration, Central Pharmacy of Tunisia and pharmaceutical industry. Obviously, we notice that 
the majority of pharmacy graduate students are more willing to opt for the private sector i.e. opening 
pharmacies  than  for  the  field  of  pharmaceutical  research  (WHO,  2003).  This  shows  the  lack  of 
inventive spirit within pharmacy students and explains the very low percentage of pharmacist working 









                                                 
12 They are waiting for the agreement of the public health ministry that allows them to establish their own pharmacies. 
13 The Arab Maghreb Union includes five countries of North Africa: Algeria, Libya, Mauritania, Morocco and Tunisia.   14
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Indeed, the graph above shows that less than half of graduate pharmacy students carry out third cycle 
studies. The faculty of pharmacy of Monastir has founded three laboratories and 18 research units in 
different specialties; such as pharmacology, hematology, immunology and control of pharmaceuticals 
quality. However, we notice that graduate students generally choose to carry out their pharmaceutical 
studies in developed countries (especially in Europe, Gulf countries and the United States) to benefit 
from more appropriate conditions for research, especially in terms of financing and access to some 
essential raw materials that are not available in Tunisia. In this context, according to the survey led in 
2006  by  the  Ministry  of  Higher  Education,  Scientific  Research  and  Technology  of  Tunisia,  we 
perceive 65 Tunisian pharmacy researchers living and working abroad. Almost 75,5% of them (49 
researchers) are in Europe, 20% in gulf countries (13 researchers) and 4,5% (3 researchers) in the 
United States (MHESRT, 2006a).  
 
2.1.2. Financial Resources  
 
In response to the international challenges, the economic policy in Tunisia aims at establishing an 
economy of knowledge. In this purpose, the government insists on enhancing the investment in R&D 
and facilitating the access to information and knowledge. In fact, the activity of R&D in Tunisia is 
obviously in progress. This is thanks to the increase of funding dedicated to scientific research and 
technology. The graph below describes the evolution of the expenses in R&D in Tunisia in percentage 
of GDP, over the period going from 1997 to 2007.  
Graph -7- Evolution of IERD
14 in Percentage of GDP in Tunisia (1997-2007
15) 
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Ministry of Higher Education, Scientific Research and Technology, Tunisia,(MHESRT, 2006b) 
 
As shown in the graph above, the part of the IERD in percentage of GPD has considerably grown up 
during the last decade from 0,43% in 1997 to 1,13% in 2007. Predicted values for 2008 and 2009 are 
                                                 
14 IERD: Internal Expenditures on Research and Development. 
15  For  2006  and  2007,  the  values  on  the  graph  are  predicted  values  by  the  MHESRT  (2006).  These  figures  were 
overestimated since the real values are respectively 1,04% in 2006 and 1,11% in 2007 (MHESRT, 2008).   15
respectively 1,19% and 1,25%. These figures seem to be satisfactory especially when compared with 
the situation in some southern European countries such as Italy (1,05%), Spain (0,96%) and Portugal 
(0,83%) in 2001. Due to the lack of statistics divided by sector of activity, we have been led to present 
the aggregate data. The aggregate data could give at least a general idea of the structure of R&D in 
Tunisia. In the graph below, we represent the distribution of public funding to R&D among ministries. 
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Ministry of Higher Education, Scientific Research and Technology, Tunisia (MHESRT, 2006a) 
 
We notice that the Tunisian government focuses much on education and academic R&D to which it 
allocates a share of 70% of the funding dedicated to research in 2005, while the ministry of public 
health holds the second share (14%). In Tunisia, the government plays the major role in financing the 
activity of R&D, with a part of 91% in 2000. Over the last eight years, this part has declined, reaching 
72%  in  2006.  The  economic  policy  in  Tunisia  aims  at  reducing  more  and  more  this  part  and  at 
improving  the  contribution  of  private  enterprises  and  especially  of  international  cooperation  in 
financing R&D projects. The graph below describes the distribution of the IERD per financing source. 
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Ministry of Higher Education, Scientific Research and Technology, Tunisia (MHESRT, 2006b; 2008) 
 
In these conditions, relying on public funds to finance R&D in a limited-income country like Tunisia 
seems  an  obstacle  for  the  development  of  the  local  activity  of  innovation  especially  in  the 
pharmaceutical sector which requires substantial funding. Therefore, we could conclude that the most 
braking factor to pharmaceutical innovation in Tunisia is the lack of financial resources. In spite of the 
measures taken by the government, the funds dedicated to scientific and technological research remain 
insufficient  to  establish  a  well  based  R&D  activity  in  Tunisia.  In  fact,  researches  in  general  and 
especially in the fields of pharmaceuticals, require huge funding. In this context, as an example, we 
mention  that  some  pharmaceutical  multinationals  dedicate  about  15%  of  their  turnovers  to 
reinvestment  in  R&D;  this  amount  exceeds  sometimes  the  whole  budget  of  a  small  developing 
country such as Tunisia. In opposition to theoretical researches, the distinctiveness of pharmaceutical 
researches is that they are “applied researches” and thus, they require highly equipped laboratories 
that allow researchers to put into practice their experiments. These equipments (machines, substances 
                                                 
16 MAEHR: Ministry of Agriculture, Environment and Hydraulic Resources. 
17 The values from 2007 to 2009 are predicted figures by MHESRT (2006b).    16
…) are generally very expensive. In addition, for security reasons
18, a number of developing countries 
are deprived of some chemical substances considered as dangerous but necessary for pharmaceutical 
experiments.  Subsequently,  we  restate  that  the  most  competent  Tunisian  researchers  in  the 
pharmaceutical fields are more willing to immigrate to developed countries so that they could exercise 
and  develop  their  skills.  This  movement,  called  as  the  phenomenon  of  “brains  immigration”, 
contributes at generating a sort of “impoverishment” in local human resources and brakes more and 
more the activity of innovation in Tunisia (Yacoub, 2008a). 
 
2.1.3. An Overview on the Tunisian Infrastructure 
 
Even though Tunisia is a small developing country, it dedicates a particular attention to ameliorate the 
quality of the local infrastructure especially in terms of logistics and technologies of information and 
communication. Over the period from 1990 to 2001, the government has set aside 10 million US 
dollars  for  investment  in  infrastructure.  Geographically,  Tunisia  is  at  a  strategic  position  and 
represents a real platform as much for investment as for trade and production, which facilitates the 
exchanges in terms of raw materials and products through 8 commercial ports and 7 international 
airports
19 (MDIC
20, 2008). As well as the transport infrastructure, the telecommunication sector seems 
to  record  an  important  development  (MCT
21,  2008).  In  fact,  Tunisia  disposes  of  fully  digitalized 
telephone network covering 100% of the national territory and allowing access to more than 170 
countries and an internet network covering all the country. The national policy aims at improving the 
society  of  knowledge  in  Tunisia  in  order  to  guarantee  a  continuous  access  to  information  by 
guaranteeing the openness to other countries, especially developed ones and the dissemination of the 
digital culture among Tunisian people. 
 
2.2. The Throughputs of Pharmaceutical Innovation in Tunisia 
 
We restate that due to the lack of sector-based statistics, we are led to use aggregate data. Actually, 
throughput indicators have a general dimension and are thus hard to quantify. To measure this kind of 
indicators, we will refer basically to the existence of a permanent R&D department within enterprises 
and on the sources  and the means of acquisition of information (Hertog  & Brouwer, 2000).  The 
survey carried out in 2005 by the Tunisian Ministry of Higher Education, Scientific Research and 
Technology,  reveals  that  over  the  586  private  Tunisian  enterprises  surveyed,  less  than  half  (248 
enterprises, which makes 42,3%) declared having led an activity of R&D.   
Table -3- Distribution of Enterprises in terms of Activity of R&D (2002-2004) 
 
Enterprises 
having a R&D 
activity 
Enterprises 
setting aside a 





Number   %  Number  %  Number  % 
No  338  57,7%  156  62,9%  86  34,7% 
Yes  248  42,3%  92  37,1%  162  65,3% 
Total number  586  248  248 
Ministry of Higher Education, Scientific Research and Technology, Tunisia (MHESRT, 2005) 
 
                                                 
18 Some developing countries are deprived from these substances either due to the lack of experience within the local 
laboratories or else to avoid the spread of terrorism in some Arab countries in particular, when these substances could be 
used as inputs to produce bombs. 
19 An eighth international airport is currently under construction in Tunisia. The investment is undertaken by the Turkish 
firm “TAV” which aims -throughout this project- at building the most important intercontinental airport in Africa. The 
airport is expected to be inaugurated by the year 2009. 
20 Ministry of Development and International Cooperation of Tunisia. 
21 Ministry of Communication Technologies of Tunisia.   17
Over the 248 enterprises, 65,3% declare having managed a continuous R&D activity between 2002 
and 2004; the activity of R&D within the other 86 enterprises (34,7%) is still occasional. However, 
only 37,1% of enterprises that run a continuous activity of R&D set aside a special budget to this 
activity. In a similar vein, the survey has analyzed the organisational structure of R&D enterprises. 
The results show that while only 22% of the questioned firms do have their own department of R&D, 
58% of them choose to entrust the activity of R&D to external institutions such as research bureaus 
(27%) and method bureaus (31%).  
Graph -10- The Organisational Structure of R&D of Enterprises (2002- 2004) 
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Ministry of Higher Education, Scientific Research and Technology, Tunisia (MHESRT, 2005) 
 
It is obvious that the activity of innovation within Tunisian enterprises is still primitive. In these 
conditions, the government has a lot of work to do longer in order to improve investment in research 
and technology by implementing the spirit of innovation within firms. This is as much realizable as 
the Tunisian economy could eliminate a number of factors susceptible to foil the development of a 
special department of R&D within firms. According to the surveyed firms themselves, developing a 
special structure of R&D within the firm is a very costly organisation which is handicapped mainly by 
the small size and by the lack of financial resources of Tunisian enterprises. For these reasons, we 
notice  that  some  Tunisian  enterprises  have  access  to  R&D  outputs  from  developed  countries 
throughout licenses or subcontracting with foreign firms, hence, they do not require managing local 
investment in R&D. 
 
2.3. The Outputs of Pharmaceutical Innovation in Tunisia 
 
The outputs of innovation are measured in general by the number of scientific publications and most 
of all by the number of patent grants. In fact, according to researchers, patents are considered as the 
most revealing indicator to measure innovation output. That is why  we are  going to use data  on 
pharmaceutical publications (2.3.1) as well as data on pharmaceutical patent applications in Tunisia 
(2.3.2).  
 
2.3.1. Growth Trends in Pharmaceutical Publications in Tunisia 
 
Over the last 25 years, the number of scientific publications in Tunisia has considerably grown up 
from 115 in 1981 to 1010 in 2004.    18








1981 1983 1985 1987 1989 1991 1993 1995 1997 1999 2001 2003
publications
 
Ministry of Higher Education, Scientific Research and Technology, Tunisia (MHESRT, 2006a) 
 
However, we notice some drops in the growth trends of the number of publications. In fact, the graph 
above shows: a first decrease to 100 scientific publications in 1982 against 115 in 1981; a second one 
of 14% from 280 in 1992 to 240 in 1993 and lately a third one from 1023 in 2003 to 1010 publications 
in 2004. On the other hand, the number of pharmaceutical publications has notably risen up from 136 
in 2002 to 191 in 2003, which makes a growth of 40% (MHESRT, 2008). As an example, Tunisian 
employees in the subsidiary of the French laboratory Sanofi Aventis localised in Tunisia succeeded at 
developing  a  new  drug  combined  of  the  Aspégic  and  the  molecule  of  vitamin  C  and  called  it 
“Aspégic-Vitamine C”. This represents an important innovation since this new drug is the first to be at 
100% designed and produced in Tunisia. This explains that it is going to be exported exclusively from 
the  subsidiary  localised  in  Tunisia  (FIPA,  2006).  However,  the  decrease  in  the  total  number  of 
publications by the year 2004, has also affected the pharmaceutical domain, since the number has 
fallen down from 191 in 2003 to 186 pharmaceutical publications in 2004. 









Ministry of Higher Education, Scientific Research and Technology, Tunisia (MHESRT, 2008) 
 
As  well  as  in  terms  of  the  total  number,  the  share  of  pharmaceutical  scientific  publications  (in 
percentage of the total scientific publications) has grown up, reaching 18,7% in 2003 against 16,5% in 
2002, but afterwards, has lightly declined in 2004 to a level of 18,4%. We notice that this decrease 
happens together with the decline of the number of graduate pharmacy students (from 1280 in 2003 to 
1270  in  2004).  In  addition,  according  to  the  MHESRT  (2006a)  statistics,  this  decline  has  been 
compensated by the increase of the number of publications in other scientific fields between 2003 and 
2004, such as social sciences, agriculture and biology and especially engineering, computer science 
and technology whose share are grown up to 384 in 2004 against 510 publications in 2003. 
 
2.3.2. Pharmaceutical Patents Indicators in Tunisia 
 
Patent applications and patent grants are considered as the major indicator to evaluate a country’s 
potential of innovation. Patents are supposed to be an input as well as an output innovation indicator. 
On the one hand, patent is used to protect the result of the activity of innovation; it is perceived in this   19
case  as  an  “output”  indicator  of  innovation.  On  the  other  hand,  information  and  knowledge  -
incorporated in the patent- and revealed once the patent disclosed, will be used as a basis for further 
researches, either by the patent holder himself or by any other third parties; in this case, the patent is 
perceived as an “input” indicator of innovation. If we consider here patent statistics as an output 
indicator of the activity of R&D in Tunisia, we notice that the number of patent applications remains 
low and more precisely, that the contribution of Tunisian enterprises remains marginal. Over the last 
eight  years, the INNORPI
22 receives an average number of 250 patent applications per year. The 
following graph shows that the growth trends in patent applications have recorded both ups and downs 
over the last decade. In fact, the number of patent applications collapsed by 150%: from 257 in 2000 
to 103 in 2002, but has recovered from then on, achieving 456 patent applications by the year 2006, 
which makes a boost rate of 35% with regard to 2005 and of 77% with regard to 2000. 
Graph -13- Total Patent Applications in Tunisia (2000- 2006) 





















INNORPI, Tunisia, 2008. 
 
Another revealing character of patent applications in Tunisia is that most of them are filed by foreign 
applicants. In fact, from 1984 and 1994, there have been a total number of 1720 patent applications, of 
which only 285 (16,6%) were filed by domestic enterprises, the other 1435 patents were filed by 
foreign firms (Visentin, 2005). We notice the same trends from 2000 to 2007. 
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INNORPI, Tunisia, 2008. 
 
According to the INNORPI data, we notice that the share of foreign patent applications in Tunisia is 
very important (at an average level of 80%). Although it has declined to a proportion of 56,3% in 
2002,  it  is  from  then  on  continuously  increasing,  reaching  84%  in  2006.  Besides,  even  the  drop 
noticed in 2002 is explained more by the decrease of the number of foreign patent applications (a drop 
of 167% with regard to 2001) rather than by the increase of domestic patent applications (a rise of 
104%  with  regard  to  2001).  The  US  firms  are  the  most  important  patent  applicants  in  Tunisia, 
representing 27% of the total number of patent applications in 2006. Tunisians are at the second rank 
with 73 applications (16%), French at the third with 68 patent applications (15%), Swiss at the fourth 
                                                 
22 Institut National de la Normalisation et de la Propriété Industrielle : National Institute for Standardization and Industrial 
Property.   20
with 66 applications (14%), German at the fifth with 34 applications (7,5%) and Italian at the sixth 
with  20  applications  (4,4%).  In  this  framework,  patent  analysis  confirms  that  the  contribution  of 
Tunisians in the activity of innovation remains at a low level, especially among private enterprises. 
Actually,  according  to  the  INNORPI,  individuals  hold  the  biggest  share  of  patent  applications  in 
Tunisia (53%) of 288 patent applications
23 between 2000 and 2006. 
Graph -15- Domestic Patent Applications within Different Types of Applicants 
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This share has reached 60,3% in 2006 while the contribution of private enterprises still stands at 7 
patent applications, which makes a share of 9,3%. These figures show that the government should 
focus more on improving the activity of innovation within private firms. On a scetoral level, over the 
total number of patent applications in Tunisia between 1984 and 1994, there have been only 297 
pharmaceutical patents, representing a share of 17,3%. Only 8 (2,7%) of these 297 pharmaceutical 
patents were filed by Tunisian enterprises while 289 (97,3%) patent applications were filed by foreign 
laboratories (INNORPI, 2008). From 1995 to 2001, the number of pharmaceutical patent applications 
at the INNORPI has grown up to 348 and then to 800 by the end of 2004 (El Kateb, 2005). These 
applications have been accepted in mail box. The procedures for their grant were postponed to January 
2005
24.  
Table -4- Pharmaceutical Patent Applications in Tunisia (1984-2001) 
Years  1984-
1994  1995  1996  1997  1998  1999  2000  2001  Total 
number 
Number of 




USA  -  8%  62%     71%  83%  95%  95%  100%  - 
Sweden  -  33%  15%  10%  10,5%  4%  5%  -  - 
France  -  8%  23%  19%  6,5%  1%  -  -  - 
Germany  -  51%  -  -  -  -  -  -  - 
WHO (2003, p107) 
 
As shown in the table 4, German pharmaceutical firms had hold more than 50% of patent applications 
in Tunisia. However, we notice that since 1996, US pharmaceutical laboratories are holding the main 
part of patent applications in Tunisia, with more than 60% of a total number of 34 applications, 
followed by French laboratories with a share of 23%. However, from then on, French laboratories 
have given up their place to Swedish laboratories whose share has reached 10,5% in 1998 against 
6,5% for French pharmaceutical firms. By the year 2001, 100% of the patent applications received by 
the INNORPI were all filed by US laboratories. 
 
                                                 
23 By the end of 2006, 324 domestic patent applications have been recorded in Tunisia. Almost 11% of them (36) are filed 
by other domestic applicants unidentified by the INNORPI. 
24 The mail box regime was abolished by the expiry of the transitory period granted to Tunisia until January 2005. From 
then on, pharmaceutical patents Tunisia are granted in accordance with the TRIPs’ agreement.   21
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In fact, we notice a considerable pre-eminence of US pharmaceutical patents granted by the INNORPI 
(46% in 2006 and 40% in 2007) while the contribution of nationals remain at a marginal level with a 
maximum number of four patents in 1996, 2001 and 2006 and just one patent granted in 2007.  
Again, in addition to the other indicators, the marginal number of Tunisian patents confirms the lack 
of technological innovation in Tunisia in general and in the pharmaceutical sector in particular. In 
these conditions, what are the perspectives for growth and innovation in the Tunisian pharmaceutical 
industry? And what ameliorations should be brought to the pharmaceutical innovation system in order 
to benefit from patent enforcement? 
 
2.4. Perspectives for Innovation in the Tunisian Pharmaceutical Sector 
 
The incentives for innovation are narrowly related to the market structure. Consequently, the activity 
of innovation is narrowly connected to patent protection, since patent rights influence the market 
structure. Although from this point of view the role of patents as an incentive for innovation seems to 
be  obvious,  studies  on  their  impact  on  the  activity  of  innovation  reveal  controversial  results.  To 
explain this ambiguity, Combe & Pfister (2001) argue that innovation depends on several determinant 
factors (such as the firm’s size, financial capabilities, the market concentration and opportunities … 
etc). Although patent protection is one of the most important of these factors, it is difficult to isolate 
their effect on innovation. Also, since establishing patent systems remains relatively recent, especially 
in developing countries, their effects on innovation have not been shown up yet. Indeed, the activity of 
innovation in a country requires a long-run period to be studied. Empirical studies reveal that patent 
protection in pharmaceuticals is supposed to be an incentive for innovation in developed countries 
(Saggi,  2000;  Schneider,  2005;  Xu&Chiang,  2005;  Lévêque,  2006).  Nonetheless,  in  developing 
countries, where the activity of innovation is handicapped by the lack of production and technologies 
absorption  capabilities,  pharmaceutical  patents  are  expected  to  reduce  the  innovation  through 
imitation but do not play a major role in promoting technological innovation. 
 
Consequently,  in  Tunisia  -as  characterised  by  limited  financial  resources,  a  small  market  size, 
insufficient technological capabilities …- it is difficult to found a local pharmaceutical industry that 
could allow its independence from imports (Yacoub, 2008b). Therefore, with pharmaceutical patents 
in Tunisia, brand name drugs are expected to become more expensive and thus the accessibility of 
lower-income consumers will be reduced. At the same time, it is true that Tunisia has promising 
innovation inputs, especially in terms of human resources, infrastructure and statutory institutional 
incentives, but the financial obstacle represents, in addition to the centralized structure of the Tunisian 
innovation system, a major brake that inhibits the development of the activity of innovation.  
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Table - 5 - Balance-Sheet of Innovation Strengths and Weaknesses in the Tunisian Economy 
   Strengths    Weaknesses  
+ qualified local human resources 
+ local market with a promising potential of production 
+ a good infrastructure especially in terms of 
telecommunications 
+ an encouraging legal framework for innovation 
- passive spirit towards innovation 
- small local market and firms size 
-  bureaucratic  and  centralized 
system  
- limited financial resources 
Source: Yacoub (2008a) 
 
In this context, and on the basis of the inventory of fixtures of the Tunisian innovation capabilities, we 
can conclude that pharmaceutical patent protection in Tunisia seem to have an insignificant effect on 
enhancing technological innovation since the brakes for innovation in Tunisia are related to more 
important factors, the most important of them are the lack of financial resources and some structural 
deficiencies  of  the  innovation  system.  On  the  other  hand,  it  is  obvious  that  Tunisia  presents  a 
promising  potential  of  production,  especially  in  the  industry  of  generics  and  in  these  conditions, 
pharmaceutical  patent  protection  “might”  be  an  incentive  for  minor  innovation,  in  the  sense  of 
ameliorating existing drugs and adapting them to the characteristics and needs of the local market, 
provided  that  the  government  proceed  at  some  imperative  corrective  measures,  especially  by 
improving  the  interactions  between  the  industrial  and  the  educational  sectors,  by  enhancing  the 
research valorisation, by reducing bureaucracy and centralisation, by looking for new alternatives for 
funding  through  cooperation  programs  with  foreign  investors,  …  etc.  In  fact,  globally,  the  main 
challenge  associated  to  patent  rights  is  to  establish  a  “fair  balance”  between  incentives  for 
technological innovation and the dissemination of technologies. Economically, this means that patent 
protection has to guarantee a sort of a “trade-off” between dynamic efficiency and static efficiency. 
The establishment of this trade-off remains difficult to reach though (Lévêque & Ménière, 2004). In 
this context, Tunisian pharmaceutical firms could benefit from the imperfection of patent rights and 
invest in innovating “behind” (related to patent length), “aside” (related to patent breadth) or “above” 
(related to patent height) the pharmaceutical patent (Van Dijk, 1994) in order to bring improvement to 
already existing drugs.  
Globally,  patent  protection  in  the  Tunisian  pharmaceutical  sector  generates  differentiated  effects, 
whether we talk about the short or the long term. In the short term, as we have shown, pharmaceutical 
patents have been associated to a generics-based pharmaceutical industry in Tunisia. As for the long 
term, the impacts are not perceived yet, but two potential effects are possible: either the same short-
term impacts will persist, or by building and developing the local innovation capabilities. In fact, 
pharmaceutical firms require more important funds than those devoted by the state in order to engage 
investment in R&D, the results inherent to these researches are not always positive, though. For these 
reasons, it is true that it seems more workable for Tunisia to focus on the short-term solution; the 
production of generics and licensed drugs. However, at the same time, the government should keep a 





Strengthening patent rights and their extension to pharmaceuticals in Tunisia were an obligatory step 
inherent to the entrance to the WTO. However, it is imperative for the country to make this event 
profitable for the local economy, especially in terms of enhancing the technological innovation. In this 
context,  we  restate  that  the  relationship  between  patent  and  innovation  remains  controversial 
(Laperche, 2004). On the one hand, it is obvious that more improved  pharmaceutical patents  are 
expected to increase the attractiveness of the Tunisian economy towards pharmaceutical multinational 
firms  which  represent  a  vector  of  technology  transfer  and  hence  of  improving  the  activity  of 
innovation in Tunisia. On the other hand, due to the insufficient innovation and absorption capabilities 
in Tunisia, the local firms can not perfectly benefit from this technology transfer. In this sense, the   23
government should emphasize on improving the intrinsic innovation capabilities within local firms in 
addition  to  insisting  on  the  advantages  of  patents  in  terms  of  drawing  foreign  pharmaceutical 
investments.  In  this  context,  Tunisia  has  to  put  more  attention  on  developing  its  national  and 
pharmaceutical  innovation  systems,  especially  by  improving  the  local  competences  and  the 
interactions between the different actors, not only within and the pharmaceutical sector (laboratories, 
CPT,  medical  institutions,  …)  but  also  with  other  actors  (public  entities,  universities,  financial 
institutions, firms in other sectors, …). 
 
In general, Tunisia has indeed put into practice several measures to consolidate its innovation system; 
the  results  show  that  it  still  needs  to  retarget  its  goals  though.  Taking  the  special  case  of  the 
pharmaceutical industry, the Tunisian government has to focus as much on the long-term challenges 
by improving technological innovation as on the short-term benefits generated by the production of 
generics.  Although  generics  allow  the  access  of  Tunisia  to  cheaper  pharmaceuticals,  they  still 
represent a short-term and thus a “defensive” policy against the continuous increase of brand name 
medicines (Yacoub, 2008a). Nevertheless, certainly in the new international economic context, where 
innovation and competences development play a major role in economic progress, the government 
should stress more on encouraging technological innovation. Therefore, Tunisia is called to retarget its 
pharmaceutical policy towards defining long-term pharmaceutical strategies, especially by developing 
competences, looking for new alternatives for assuring financial resources, increasing the interactions 
between universities and the pharmaceutical industry … etc. 
 
This is as much realisable as the government consolidates the national innovation system especially 
through consolidating the interactions between the different actors. In this purpose, some corrective 
measures seem to be imperative: 
-  Puts  into  place  encouraging  measures  that  target  the  pharmaceutical  industry  taking  into 
consideration  the  specific  characteristics  of  the  sector  which  are  different  from  the  other 
manufacturing  sectors.  In  other  words,  we  notice  that  the  programs  put  into  place  in  order  to 
encourage the innovative firms are not sectorally differentiated. In fact, sectors present very different 
characteristics; in this sense, a measure which is an incentive for innovation in textile for example, 
could be insignificant for the pharmaceutical innovation; 
-  Improves  the  cooperation  between  local  pharmaceutical  enterprises  and  foreign  laboratories, 
especially in terms of financing and subcontracting; 
-  Assures more transparency and reduces bureaucracy in order to facilitate access to information and 
knowledge; 
-  Encourages pharmacy students to carry out third cycle studies in Tunisia and at the same time 
allows  them  to  benefit  from  foreign  experiences  by  assuring  exchanging  programs  with  foreign 
pharmacy students; 
-  Provides advantages to attract pharmaceutical foreign direct investments in order to benefit from 
technological transfer; 
-  Puts into effect a patent regime that stimulates innovation and the diffusion of knowledge and, at 
the same time, does not affect negatively the objectives of the health policy. 
 
Once these objectives achieved, it would be possible to talk about the eventual positive impacts of 
patent protection on the pharmaceutical innovation in Tunisia. And to conclude, we highlight that 
Tunisian pharmaceutical laboratories should not forget that pharmaceuticals remain strategic products 
which have to be, at the same time: available, affordable and especially high quality products. These 
particular characteristics of pharmaceuticals increase the challenge for the Tunisian laboratories. To 
conclude about the legitimacy of pharmaceutical patents in Tunisia, we approve that public policies, 
the legal and judiciary architecture, financing mechanisms and socioeconomic practices are very the 
key institutional and environmental determinants of innovation capabilities and R&D activities in a 
country. In this context, certainly strengthening the patent system is insufficient all alone to kick-start 
and eventually to promote the local activity of innovation. Nevertheless, it remains an imperative 
condition  that  guarantees  for  potentially  innovative  enterprises  the  possibility  of  preserving  their   24
competitive advantage. Consequently, Tunisia has to adopt a more “voluntarist” national innovation 
system to create incentives for R&D, especially by calling for resources to finance innovation next to 
foreign institutions, by establishing international partnerships and by targeting and upgrading more the 
human resources on the social dimension in order to transform the local spirit from an “innovation 
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